← Back to Search

Neuromodulation

Neuromodulation for Depression

N/A
Recruiting
Led By F. Andrew Kozel, M.D., M.S.C.R., D.F.A.P.A.
Research Sponsored by Florida State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinically competent to give informed written consent and ability to understand study procedures and to comply with them for the entire length of the study
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline over 10 weeks
Awards & highlights

Study Summary

This trial will test whether two non-invasive therapies, Virtual Reality and Transcranial Magnetic Stimulation, are effective in treating patients with dysphoria, a symptom of unease or dissatisfaction experienced across a range of diagnoses.

Who is the study for?
This trial is for adults over 18 with dysphoria, which can be part of depression or pain conditions. Participants must have stable medication and therapy for a month before the study and not change them during it. They need to be able to consent and follow the study's procedures. Excluded are those at suicide risk, with severe mental disorders like schizophrenia, significant hearing or vision loss, unstable medical conditions, substance abuse issues, non-English speakers, pregnant women, prisoners.Check my eligibility
What is being tested?
The trial tests two neuromodulation treatments: Guided Meditation using Virtual Reality (VR) to provide sensory experiences that may ease dysphoria; Accelerated Transcranial Magnetic Stimulation (TMS), where magnetic pulses stimulate brain neurons quickly compared to traditional TMS schedules. The goal is to see if these treatments are effective and practical.See study design
What are the potential side effects?
Potential side effects from VR might include dizziness or nausea due to motion sickness. For accelerated TMS possible side effects could include scalp discomfort at the treatment site during stimulation sessions, headache after treatment sessions or in rare cases seizures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I understand the study details and can follow its requirements.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline over 10 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline over 10 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Arm 1 Hypothesis 1
Arm 1 Hypothesis 2
Arm 1 Hypothesis 3
+7 more

Trial Design

3Treatment groups
Active Control
Group I: Guided Meditation VR for WellnessActive Control1 Intervention
Selected modules of commercially available meditation VR
Group II: Accelerated Transcranial Magnetic Stimulation: Treatment AActive Control1 Intervention
Intermittent theta-burst over dlPFC
Group III: Accelerated Transcranial Magnetic Stimulation: Treatment BActive Control1 Intervention
Intermittent theta-primed 10Hz over mPFC

Find a Location

Who is running the clinical trial?

Florida State UniversityLead Sponsor
199 Previous Clinical Trials
31,591 Total Patients Enrolled
6 Trials studying Depression
1,291 Patients Enrolled for Depression
F. Andrew Kozel, M.D., M.S.C.R., D.F.A.P.A.Principal InvestigatorFlorida State University

Media Library

Accelerated Transcranial Magnetic Stimulation: Treatment A (Neuromodulation) Clinical Trial Eligibility Overview. Trial Name: NCT05061745 — N/A
Depression Research Study Groups: Guided Meditation VR for Wellness, Accelerated Transcranial Magnetic Stimulation: Treatment A, Accelerated Transcranial Magnetic Stimulation: Treatment B
Depression Clinical Trial 2023: Accelerated Transcranial Magnetic Stimulation: Treatment A Highlights & Side Effects. Trial Name: NCT05061745 — N/A
Accelerated Transcranial Magnetic Stimulation: Treatment A (Neuromodulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05061745 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are any vacancies available for inclusion in this research project?

"As indicated on clinicaltrials.gov, this medical trial is still recruiting participants for inclusion. The initial post was made on September 29th 2021 and the most recent update was November 17 2022."

Answered by AI

What is the participant count for this medical research?

"Affirmative. According to the clinicaltrials.gov page, this medical trial is presently seeking participants since it was first posted on September 29th 2021 and updated lastly on November 17th 2022. 100 volunteers are needed at one site in order for this study to succeed."

Answered by AI

Who else is applying?

What site did they apply to?
Florida State University
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

Moderate depression, concerned it will get worse with time.
PatientReceived no prior treatments

What questions have other patients asked about this trial?

How many treatments? Will an enclosed MRI be required?
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Neuromodulation for Dysphoria
F. Andrew Kozel 2021. "Neuromodulation for Dysphoria". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05061745.
~9 spots leftby Aug 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top